Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy

Prog Cell Cycle Res. 2003;5:441-6.

Abstract

The ubiquitin/proteasome-dependent protein degradation pathway plays an essential role in both up-regulation of cell proliferation and down-regulation of cell death in human cancer cells. The idea that proteasome function is required for tumor cell survival has prompted the design, synthesis and evaluation of various pharmacological proteasome inhibitors. Both in vitro and in vivo experimental and clinical results have demonstrated the potential use of proteasome inhibitors as novel anticancer drugs.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Cell Cycle / drug effects*
  • Cell Cycle / genetics
  • Cell Survival / drug effects
  • Cell Survival / physiology
  • Cysteine Endopeptidases / metabolism
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Multienzyme Complexes / antagonists & inhibitors*
  • Multienzyme Complexes / metabolism
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Neoplasms / metabolism
  • Proteasome Endopeptidase Complex

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Multienzyme Complexes
  • Cysteine Endopeptidases
  • Proteasome Endopeptidase Complex